Akebia Therapeutics, Inc.AKBA

Market cap

$438.6M

P/E ratio

	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Product	-	-	-	-	7	111	129	142	177	170	152
License, collaboration and other revenue	-	-	-	-	201	224	166	71	116	24	8
Total revenues	-	-	-	-	208	335	295	214	293	195	160
Cost of product and other revenue	-	-	-	-	-	-	149	117	49	38	27
Cost, Amortization	-	-	-	-	-	-	32	36	36	36	36
Total cost of goods sold	-	-	-	-	8	145	296	153	85	74	63
Research and development	25	43	116	231	291	323	218	148	129	63	38
Selling, general and administrative	-	-	-	-	87	149	154	174	139	100	107
License	-	-	-	-	0	4	3	3	3	3	3
Restructuring	-	-	-	-	-	-	-	-	16	0	0
Total operating expenses	38	62	138	258	378	476	376	326	287	167	147
Loss from operations	-38	-62	-136	-80	-178	-286	-376	-265	-79	-46	-50
Interest expense	-	-	-	3	6	1	-9	-20	-16	-6	-18
Other income	-	-	-0	0	0	-1	2	2	3	1	0
Change in fair value of warrant liability	-	-	-	3	-	-	-	-	-	-	0
Loss on extinguishment of debt	-	-	-	-	-	-	-	-	-1	-	-1
Loss on termination of lease	-	-	-	-	-	-	-	-	-	-0	-
Net loss before income taxes	-	-	-	-	-172	-286	-383	-283	-93	-52	-69
Net loss	-37,034,039	-61	-136	-77	-144	-280	-383	-283	-93	-52	-69
Comprehensive loss	-37	-61	-136	-77	-143	-279	-383	-283	-93	-52	-69
Earnings Per Share, Basic	-	-	-	-	-	-	-	-1.7	-0.51	-0.28	-0.33
Earnings Per Share, Diluted	-	-	-	-	-	-	-	-1.7	-0.51	-0.28	-0.33